# A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

> **NCT01331941** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 35 (actual)

## Conditions studied

- Advanced Solid Tumors
- Kidney Disease
- Renal Impairment

## Interventions

- **DRUG:** AMG 386 + Paclitaxel
- **DRUG:** AMG 386

## Key facts

- **NCT ID:** NCT01331941
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-19
- **Primary completion:** 2013-02-26
- **Final completion:** —
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331941, "A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01331941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*